Veracyte Announces Participation in Upcoming Investor Conferences
February 20, 2019
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte,
Inc. (Nasdaq: VCYT) today announced that members of its management
team will be participating in two upcoming investor conferences.
Executives from the company will be meeting with investors at the BTIG
MedTech, Life Science & Diagnostic Tools Conference 2019 on Wednesday,
February 27, 2019, in Snowbird, Utah. There will not be a webcasted
presentation.
Bonnie H. Anderson, chairman and chief executive officer, is scheduled
to present at the 8th Annual SVB Leerink Global Healthcare
Conference in New York City on Friday, March 1, 2019 at 9:00 a.m. EST. A
live audio webcast of the company’s presentation will be available by
visiting Veracyte’s website at http://investor.veracyte.com/events-presentations.
A replay of the webcast will be available for 90 days following the
conclusion of the live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that
improves patient care by providing trustworthy and actionable answers to
challenging clinical questions. The company’s products uniquely combine
advanced genomic technology, clinical science and machine learning to
provide answers that give physicians and patients a clear path forward,
informing both diagnosis and treatment decisions without the need for
costly, risky surgeries that are often unnecessary. Since its founding
in 2008, Veracyte has commercialized three genomic tests, which are
transforming the diagnosis of thyroid cancer, lung cancer and idiopathic
pulmonary fibrosis. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
Contacts
Veracyte Media & Investor Contact:
Angie McCabe
Vice
President, Investor Relations & Corporate Communications
650-243-6371
angie@veracyte.com